Annual Total Long Term Liabilities
$606.87 M
-$151.54 M-19.98%
December 31, 2023
Summary
- As of February 7, 2025, PCRX annual total long term liabilities is $606.87 million, with the most recent change of -$151.54 million (-19.98%) on December 31, 2023.
- During the last 3 years, PCRX annual total long term liabilities has risen by +$205.38 million (+51.15%).
- PCRX annual total long term liabilities is now -26.33% below its all-time high of $823.83 million, reached on December 31, 2021.
Performance
PCRX Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Long Term Liabilities
$465.71 M
-$209.15 M-30.99%
September 30, 2024
Summary
- As of February 7, 2025, PCRX quarterly total long term liabilities is $465.71 million, with the most recent change of -$209.15 million (-30.99%) on September 30, 2024.
- Over the past year, PCRX quarterly long term liabilities has dropped by -$143.54 million (-23.56%).
- PCRX quarterly long term liabilities is now -46.89% below its all-time high of $876.83 million, reached on March 31, 2022.
Performance
PCRX Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Long Term Liabilities Formula
Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities
PCRX Long Term Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -20.0% | -23.6% |
| 3 y3 years | +51.1% | -46.9% |
| 5 y5 years | +97.4% | -46.9% |
PCRX Long Term Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -26.3% | at low | -46.9% | at low |
| 5 y | 5-year | -26.3% | +64.7% | -46.9% | +26.9% |
| alltime | all time | -26.3% | +9056.2% | -46.9% | +7286.3% |
Pacira BioSciences Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $465.71 M(-31.0%) |
| Jun 2024 | - | $674.85 M(+12.9%) |
| Mar 2024 | - | $597.72 M(-1.5%) |
| Dec 2023 | $606.87 M(-20.0%) | $606.87 M(-0.4%) |
| Sep 2023 | - | $609.25 M(-2.6%) |
| Jun 2023 | - | $625.49 M(-4.7%) |
| Mar 2023 | - | $656.68 M(-13.4%) |
| Dec 2022 | $758.42 M(-7.9%) | $758.42 M(-8.9%) |
| Sep 2022 | - | $832.72 M(-1.4%) |
| Jun 2022 | - | $844.17 M(-3.7%) |
| Mar 2022 | - | $876.83 M(+6.4%) |
| Dec 2021 | $823.83 M(+105.2%) | $823.83 M(+100.1%) |
| Sep 2021 | - | $411.61 M(+0.4%) |
| Jun 2021 | - | $409.97 M(+1.3%) |
| Mar 2021 | - | $404.65 M(+0.8%) |
| Dec 2020 | $401.50 M(+9.0%) | $401.50 M(-26.9%) |
| Sep 2020 | - | $549.31 M(+34.8%) |
| Jun 2020 | - | $407.38 M(+11.0%) |
| Mar 2020 | - | $367.03 M(-0.4%) |
| Dec 2019 | $368.45 M(+19.8%) | $368.45 M(+0.8%) |
| Sep 2019 | - | $365.49 M(+0.6%) |
| Jun 2019 | - | $363.19 M(+9.2%) |
| Mar 2019 | - | $332.65 M(+8.2%) |
| Dec 2018 | $307.47 M(+5.1%) | $307.47 M(+1.4%) |
| Sep 2018 | - | $303.26 M(+1.4%) |
| Jun 2018 | - | $299.14 M(+1.4%) |
| Mar 2018 | - | $295.15 M(+0.8%) |
| Dec 2017 | $292.67 M | $292.67 M(+1.3%) |
| Sep 2017 | - | $288.95 M(+0.6%) |
| Jun 2017 | - | $287.19 M(+1.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2017 | - | $283.68 M(+122.2%) |
| Dec 2016 | $127.65 M(+552.8%) | $127.65 M(+532.8%) |
| Sep 2016 | - | $20.17 M(-7.9%) |
| Jun 2016 | - | $21.91 M(+15.9%) |
| Mar 2016 | - | $18.90 M(-3.4%) |
| Dec 2015 | $19.55 M(+31.1%) | $19.55 M(+34.3%) |
| Sep 2015 | - | $14.56 M(+2.3%) |
| Jun 2015 | - | $14.24 M(-2.2%) |
| Mar 2015 | - | $14.56 M(-2.4%) |
| Dec 2014 | $14.92 M(+125.1%) | $14.92 M(-1.2%) |
| Sep 2014 | - | $15.10 M(+3.4%) |
| Jun 2014 | - | $14.61 M(+128.4%) |
| Mar 2014 | - | $6.39 M(-3.5%) |
| Dec 2013 | $6.63 M(-79.3%) | $6.63 M(+5.1%) |
| Sep 2013 | - | $6.30 M(-93.9%) |
| Jun 2013 | - | $103.45 M(+0.7%) |
| Mar 2013 | - | $102.75 M(+220.7%) |
| Dec 2012 | $32.04 M(-3.8%) | $32.04 M(-1.6%) |
| Sep 2012 | - | $32.55 M(-1.7%) |
| Jun 2012 | - | $33.11 M(-12.6%) |
| Mar 2012 | - | $37.86 M(+13.7%) |
| Dec 2011 | $33.31 M(-66.2%) | $33.31 M(-27.4%) |
| Sep 2011 | - | $45.91 M(-1.7%) |
| Jun 2011 | - | $46.68 M(-0.8%) |
| Mar 2011 | - | $47.06 M(-52.3%) |
| Dec 2010 | $98.62 M(+87.9%) | $98.62 M(+20.3%) |
| Sep 2010 | - | $81.99 M(+16.6%) |
| Jun 2010 | - | $70.33 M(+34.0%) |
| Dec 2009 | $52.49 M(+101.6%) | $52.49 M |
| Dec 2008 | $26.04 M | - |
FAQ
- What is Pacira BioSciences annual total long term liabilities?
- What is the all time high annual total long term liabilities for Pacira BioSciences?
- What is Pacira BioSciences annual total long term liabilities year-on-year change?
- What is Pacira BioSciences quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Pacira BioSciences?
- What is Pacira BioSciences quarterly long term liabilities year-on-year change?
What is Pacira BioSciences annual total long term liabilities?
The current annual total long term liabilities of PCRX is $606.87 M
What is the all time high annual total long term liabilities for Pacira BioSciences?
Pacira BioSciences all-time high annual total long term liabilities is $823.83 M
What is Pacira BioSciences annual total long term liabilities year-on-year change?
Over the past year, PCRX annual total long term liabilities has changed by -$151.54 M (-19.98%)
What is Pacira BioSciences quarterly total long term liabilities?
The current quarterly long term liabilities of PCRX is $465.71 M
What is the all time high quarterly long term liabilities for Pacira BioSciences?
Pacira BioSciences all-time high quarterly total long term liabilities is $876.83 M
What is Pacira BioSciences quarterly long term liabilities year-on-year change?
Over the past year, PCRX quarterly total long term liabilities has changed by -$143.54 M (-23.56%)